https://www.selleckchem.com/pr....oducts/trastuzumab-e
Controlled attenuation parameter (CAP) can evaluate hepatic steatosis in patients with chronic hepatitis B (CH. However, prognostic implications of CAP value remain unclear. We evaluated the association between CAP and the risk of hepatocellular carcinoma (HCC) in patients with CHB under antiviral therapy and maintained virologic response. A total of 1823 CHB patients who were taking nucleos(t)ide analogue and showing suppressed hepatitis B virus replication were analyzed. The primary outcome was incident HCC duri
Like
Comment
Share
